FIT Biotech’s cancer patent application published

FIT Biotech’s cancer patent application published

Wednesday, October 17, 2018

cheapest brand cialis Now, Kamagra is perfect as when you buy Kamagra. Second, patients who have difficulty swallowing tablets prefer viagra generico cialis a tasty gel. The first reason is that tadalafil overnight shipping its production cost is low. A chiropractor is a specialized field that can address misalignments or slight dislocations in india cheapest tadalafil your spinal bones.

FIT Biotech Oy international patent application WO 2018/185110 has now been made public. If granted, the patent will ensure FIT Biotech the exclusive rights to commercialize its technology for the treatment of cancer.

The application is for utilizing the Company’s proprietary GTU® and gtGTU® vectors for delivering therapeutic antibodies against cancer. This is in line with the Company’s strategy to bring better, safer and more cost-efficient antibodies to a market that has been generally disappointed with the cost benefits seen by the entry of biosimilars.

CEO Erkki Pekkarinen comments: “This patent application is an important milestone in the development that we continue to do in our R&D portfolio. The biological therapeutics market continues to grow at an unprecedented pace and we are well positioned to meet the demand.”

Source: Company Press Release
Key Facts
News Category: Intellectual Property
Company: FIT Biotech Oy
Country:
Europe > Finland

Leave a Reply

Your email address will not be published. Required fields are marked *

38 + = 40